💸 The Tape

Village Farms reported a third quarter that split neatly down the middle. Cannabis revenue hit a record $55.0 million, international exports jumped 75%, the company posted its sixth consecutive quarter of positive net income, and it ended September with $79.3 million in cash against $38.7 million in debt. At the same time, Canadian cannabis revenue fell 16%, cannabis gross margin compressed from 55% to 48%, and cannabis operating cash flow dropped to $7.3 million from $20.6 million. Both halves are true. Which one matters depends on whether you’re an operator or a buyer.

The export story

Start with what’s working, because it’s working better than anywhere else in Canadian cannabis. International export revenue rose to $20.8 million from $11.9 million, now 38% of cannabis sales and growing at a pace that will make it the largest segment within a year at current trajectories. Village Farms holds a leading share in Germany, has equity stakes in Australian and German distribution businesses, and its Groningen facility in the Netherlands is fully planted and heading to maximum capacity in early 2027. The company doesn’t break out exports by country, which is a disclosure gap, but the aggregate number tells the story: Pure Sunfarms is becoming an EU-GMP flower supplier that happens to sell in Canada, rather than the other way around.

Michael DeGiglio’s commentary leaned into the inflection. “Our third quarter results were driven by record cannabis revenues of $55 million,” he said, before addressing the margin squeeze head-on: wholesale trim volumes and pricing “reached trough levels” in Q3 and should normalize in Q4. That’s a specific, falsifiable claim, and it explains most of the seven-point gross margin decline. Non-branded Canadian revenue, which is largely spot trim, fell 55% to $3.3 million. When the lowest-margin product in the mix collapses in price, the blended margin falls even as the high-value export business grows.

The domestic pressure

Canadian branded revenue fell 6% to $25.3 million. The company says it holds top-five national share and is gaining in vapes and infused pre-rolls, with top-ten positions in every major category. But the Canadian rec market is flat, excise taxes are unchanged, and the only growth available is share taken from someone else. Netherlands branded revenue also fell 21%, which is a surprise given the pilot’s constrained supply, and U.S. cannabis, the CBD business, dropped 16% while awaiting clarity on the December 11 federal hemp deadline.

Consolidated net income was $10.0 million, flat year over year, with adjusted EBITDA of $18.2 million at a 27% margin against $20.7 million last year. Shares outstanding rose to 122.3 million from 115.7 million, with no buyback disclosed; the share creep appears to be equity compensation and the earlier institutional placement.

The capacity bet

Here’s where Village Farms is making its real move. Delta 2’s expansion is on track for Q1 2027, taking the facility to 40 metric tonnes by mid-year. The company has now notified Verdexa, its produce partner, that it will convert 16 acres of the 60-acre Delta 1 greenhouse to cannabis, roughly 700,000 square feet, with no formal plan yet but clear intent to have the option open for 2027. And in Texas, it’s “mobilizing” the 30-acre Monahans greenhouse for cannabis production, a direct bet on the expanded TCUP program and whatever comes after it.

That’s a company adding capacity into a market where its domestic revenue is shrinking, which only makes sense if you believe the export channel absorbs all of it. Village Farms clearly does. The question is whether it will be Village Farms that harvests those tonnes.

Could Village be next?

Organigram just agreed to pay C$7.80 a share, roughly C$561 million, for Aurora, with BAT writing a C$187.5 million check to fund it. The strategic logic was EU-GMP production, German market share, international medical growth and a clean balance sheet. Read that list again and then look at Village Farms: EU-GMP certified Delta facilities, a leading German share, 75% export growth, a Dutch cultivation license, $41 million of net cash and a stock that still trades at a single-digit multiple of adjusted EBITDA. If a buyer wanted what Aurora had, Village Farms has most of it at a lower price with a better growth rate.

The natural acquirers are obvious. Cronos, sitting on $840 million in cash with 614% international growth and a Dutch position of its own through CanAdelaar, could buy Village Farms outright and still have half a billion left. Tilray, which just consolidated its Canadian footprint and wants Masson’s EU-GMP certification back, would be acquiring the certification and the German channel it lacks. Curaleaf, having lost Aurora, has publicly stated its intention to grow internationally and needs a Canadian production base to supply Europe; Village Farms is the one left standing. Even a combined Organigram-Aurora, once closed, would look at Village Farms as the consolidation move that locks up Canadian export capacity.

The obstacles are real. DeGiglio and management are long-tenured and have shown no interest in selling. The produce business and Texas greenhouse complicate the asset profile. The Verdexa partnership and Delta 1 conversion add moving parts a buyer would have to underwrite. And Village Farms has been on takeover lists before without a deal materializing.

But that was before Organigram paid a 93% premium for a company growing international revenue at 44% while Village Farms grows it at 75%. The Aurora deal set a price for EU-GMP Canadian flower capacity, and Village Farms is now the cheapest remaining way to buy it. This is speculation, and nothing in the quarter suggests a process is underway. Still, if the consolidation chapter that opened this week has a second act, it’s hard to find a more logical target.

📈 Dog Walkers

$CMPS ( ▲ 10.24% ) Completes Submission

Compass Pathways announced Monday that it has completed its New Drug Application for COMP360, its synthetic psilocybin, for treatment-resistant depression. It’s the first psilocybin NDA ever submitted to the FDA, and the first psychedelic filing since Lykos’s MDMA application was rejected in 2024. For a sector that has spent two years recovering from that decision, this is the moment the thesis gets tested on the regulator’s terms.

The package is as strong as anything in the category. Two Phase 3 trials and a Phase 2b, each hitting its primary endpoint, across more than 1,000 participants, which CEO Kabir Nath called “the largest late-stage clinical program in psychedelic treatments.” COMP360 holds Breakthrough Therapy designation, was granted rolling review, and carries a National Priority Voucher that could compress the FDA’s timeline well below the standard ten months. Compass is guiding to a commercial launch in the first half of 2027, subject to approval, and says it already has “a world-class and fully scaled commercial organization” in place.

What the release doesn’t say is just as important. There’s no PDUFA date yet. No efficacy or safety figures from the Phase 3 program are restated, which means investors are working from prior readouts. REMS isn’t mentioned, and a psychedelic administered in a supervised session will almost certainly require one. And cash runway is absent from the body text, with the risk factors noting a continued need for funding, which is the standard language of a company about to spend heavily on launch.

The regulatory gating item sits outside the FDA. Psilocybin is Schedule I, and commercialization requires the DEA to reschedule COMP360 after approval, then the states to follow. That’s a 90-day statutory window the DEA has historically met for approved drugs, but it’s a window, not a formality, and Compass flags it explicitly.

For the psychedelics trade, this filing matters regardless of outcome. An approval validates the entire pipeline from MindMed to Cybin and reopens institutional capital. A rejection, after Lykos, would be a second strike that’s hard to recover from. Compass just put the question to the only body whose answer counts.

$ROMJ.TSX ( 0.0% ) Puts 500 Strains Under One Roof

Rubicon Organics announced Arbora, a dedicated genetics facility in Squamish, British Columbia, built to preserve, propagate and develop the company’s library of more than 500 cannabis cultivars. The site is leased, licensed by Health Canada for cultivation, and exists for a single purpose: making sure the genetics that underpin Simply Bare Organics, 1964 Supply Co., Wildflower and Homestead don’t live and die with whatever happens on the production floor.

CEO Margaret Brodie’s framing is the right one for a premium operator. “Exceptional genetics are the engine that drives premium cannabis,” she said, and Arbora “gives that library a dedicated home.” The subtext is risk management. A 500-cultivar library maintained inside a working greenhouse competes for space, light and attention with commercial crops, and a single pest or pathogen event can wipe out a decade of breeding. Separating the vault from the factory is what every serious plant-genetics business eventually does. Rubicon is doing it now, as it scales.

The timing fits the broader buildout. Pacifica, the 125,000-square-foot hybrid greenhouse in Delta, is running about 15,500 kilograms annually and heading to 20,000 by mid-2027 following the lighting upgrade funded by October’s $3 million private placement. Cascadia, the 47,500-square-foot indoor facility in Hope, handles the top-shelf indoor flower. Arbora becomes the third leg: a genetics pipeline feeding two production sites. The company’s first internally bred strain to reach market, Caviar Z, launched under Simply Bare this year, and the release makes clear Rubicon wants that to become a regular cadence rather than a one-off.

What’s missing is what’s usually missing from Rubicon releases. No square footage for Arbora, no capex, no headcount, no timeline for when proprietary genetics start carrying a meaningful share of the portfolio. The reference to “international certifications” and “regulated international markets” is vague; there’s no EU-GMP commitment and no export volume disclosed, which matters because that’s where the margin is going.

Still, the strategic logic is clean. Rubicon has carved out the premium organic niche in a Canadian market where premium is the only segment holding price. Proprietary genetics are how you defend that niche. Arbora is the company admitting its most valuable asset isn’t the greenhouses. It’s what’s growing in them.

📺 Trade To Black

Is a New Chapter Starting for Cannabis? | TTB Weekly Recap

• Democrats take the House and Senate in the midterms, Texas sends Talarico, Hinojosa and Goodwin to victory, and Massachusetts crushes Question 8 roughly 76–24. Roger Stone is urging Trump to deal with Democrats on cannabis, and Rep. Dina Titus sees bipartisan openings.

• Rescheduling enters the final stretch: final briefs are in, the stay has expired, and Judge Julius’s recommendation is next. Stephen Miller replacing Susie Wiles as chief of staff raises fresh questions for hemp ahead of the December 11 deadline.

• Q3 earnings were strong across the board: Trulieve at $230M with a 64% gross margin, Green Thumb up 11.3% to $324.4M, Curaleaf at a record $353M, and TerrAscend at $68.2M with a 13th straight quarter of positive free cash flow.

• Organigram signs a definitive deal for Aurora at C$7.80 a share, about C$561M, with BAT investing C$187.5M. Shareholder, court and regulatory approvals still to come, and Curaleaf’s bid remains outstanding.